NEUP
Neuphoria Therapeutics Inc
NASDAQ: NEUP · HEALTHCARE · BIOTECHNOLOGY
$5.27
+1.54% today
Updated 2026-04-30
Market cap
$27.76M
P/E ratio
—
P/S ratio
1.85x
EPS (TTM)
$-0.69
Dividend yield
—
52W range
$4 – $21
Volume
0.1M
Neuphoria Therapeutics Inc (NEUP) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-37.80%
Operating margin
-12.40%
ROE
-26.10%
ROA
-4.25%
Debt/equity
0.01x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $660353.00 | $-5.46M | 62.61% | -1,401.76% | -827.28% |
| 2007 | $754969.00 | $-5.04M | 72.65% | -1,250.74% | -668.10% |
| 2008 | $872709.00 | $-4.46M | 99.03% | -1,173.12% | -511.31% |
| 2009 | $1.79M | $-6.32M | 144.07% | -477.69% | -353.20% |
| 2010 | $1.70M | $-8.57M | 149.41% | -626.55% | -503.29% |
| 2011 | $2.94M | $-8.62M | 70.42% | -362.77% | -293.61% |
| 2012 | $5.34M | $-3.19M | 86.72% | -151.51% | -59.77% |
| 2013 | $2.50M | $-11.09M | 44.68% | -918.27% | -444.13% |
| 2014 | $18.73M | $3.13M | 49.11% | -19.71% | 16.70% |
| 2015 | $7.30M | $-18.56M | -110.29% | -394.06% | -254.11% |
| 2016 | $7.79M | $-16.18M | -71.13% | -363.49% | -207.75% |
| 2017 | $18.17M | $-6.65M | 15.55% | -76.21% | -36.58% |
| 2018 | $3.95M | $-26.40M | -338.38% | -771.76% | -668.33% |
| 2019 | $717528.00 | $-10.60M | -664.13% | -2,839.32% | -1,477.09% |
| 2020 | $45134.00 | $-6.89M | -6,282.59% | -25,865.53% | -15,255.78% |
| 2021 | $928073.00 | $-8.65M | -182.21% | -1,395.00% | -931.70% |
| 2022 | $277892.00 | $-22.94M | 65.26% | -10,292.02% | -8,253.64% |
| 2023 | $0.00 | $-21.65M | — | — | — |
| 2024 | $0.00 | $-23.19M | — | — | — |
| 2025 | $23.95M | $-565773.00 | 95.76% | -7.21% | -2.36% |